1314003-88-7

Upstream product

• 18144-47-3 tert-butyl 4-aminobenzoate 
• 197145-37-2 3-(dimethylamino)-1-(3-methoxyphenyl)-2-methylpropan-1-one 
• 175591-23-8 tapentadol 
• 75294-50-7 tert-butyl 4-isocyanatobenzoate 
• 175591-22-7 (βR,γR)-γ-ethyl-N,N,β-trimethyl-3-methoxybenzenepropanamine 
• 175590-76-8 (2SS,3RS)-[3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol]-dimethylamine 
• 3027-13-2 1-(3-methoxyphenyl)propan-2-one 
• 850222-40-1 (2S)-3-dimethylamino-1-(3-methoxyphenyl)-2-methyl-1-propanone 
• 850222-41-2 (S)-3-(dimethylamino)-1-(3-methoxyphenyl)-2-methylpropan-1-one (2R,3R)-O,O'-dibenzoyltartrate 

Downstream Products

• 1314003-30-9 (R,R)-tapentadol-PABA carbamate trifluoroacetate 

Relevant academic research and scientific papers

PRODRUGS OF OPIOIDS AND USES THEREOF

The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.